辅酶Q10

辅酶Q10用途

Coenzyme Q10是电子传递链的重要辅助因子,也是一种有效的抗氧化剂。

点击显示

辅酶Q10作用

1、可减轻急性缺血时的心肌收缩力的减弱和磷酸肌酸与三磷酸腺苷含量减少，保持缺血心肌细胞线粒体的形态结构，对缺血心肌有一定保护作用。
2、增加心输出量，降低外周阻力，有利于抗心衰治疗，可能抑制醛固酮的合成与分泌及阻断其对肾小管的效应。
3、在缺氧条件下灌注动物离体心室肌时，可使其动作电位持续时间缩短，产生室性心律失常阈值较对照动物高。
4、可使外周血管阻力下降，并有抗醛固酮作用。
5、辅酶Q10有抗阿霉素的心脏毒性作用及保肝作用。

点击显示

辅酶Q10名称

[ CAS 号 ]:
303-98-0

[ 中文名 ]:
辅酶Q10

[ 英文名 ]:
coenzyme Q10

[中文别名 ]:

[英文别名 ]:

coenzyme Q-10
CoQ10
Ube-Q
Coenzyme Q
Ubiquinone 50
Coenzyme Q 10
Ubiquinone 10
Coenzyme Q10
Ensorb
Liquid-Q

辅酶Q10生物活性

[ 描述 ]:

Coenzyme Q10是电子传递链的重要辅助因子,也是一种有效的抗氧化剂。

[ 相关类别 ]:

研究领域 >> 癌症

研究领域 >> 炎症/免疫

研究领域 >> 代谢疾病

研究领域 >> 神经疾病

天然产物 >> 醌类

[ 靶点 ]

Human Endogenous Metabolite

[体外研究]

辅酶Q10是所有细胞线粒体中呼吸链的必需成员。因此,它是三磷酸腺苷(ATP)形成的必需成分,三磷酸腺苷是大多数细胞过程中的能量来源。辅酶Q10位于线粒体,溶酶体,高尔基体和质膜中,通过与自由基的直接反应或生育酚和抗坏血酸从其氧化状态再生,提供抗氧化作用[1]。辅酶Q10是一种流行的膳食补充剂,因为它被公众认可为支持人类健康的重要营养素。在几种心血管和退行性神经和神经肌肉疾病中使用辅酶Q10作为治疗剂的基本原理是基于其在线粒体功能和细胞生物能量学中的基础作用[2]。

[体内研究]

由于其疏水性和大分子量,膳食辅酶Q10的吸收缓慢且有限。在膳食补充剂的情况下,溶解的辅酶Q10制剂显示出增强的生物利用度。 Tmax约为6小时,消除半衰期约为33小时。血浆辅酶Q10的参考区间在健康受试者中为0.40-1.91mM。使用辅酶Q10补充剂,血浆辅酶Q10的增加和摄入剂量之间存在合理的相关性,直至某一点。动物数据显示大剂量的辅酶Q10被包括心脏和脑线粒体在内的所有组织摄取[2]。在12个月大的大鼠中,施用辅酶Q10导致大脑皮质线粒体浓度的辅酶Q10显着增加。辅酶Q10的口服给药显着减弱了全身给予3-硝基丙酸所产生的纹状体病变,并显着延长了家族性肌萎缩侧索硬化的转基因小鼠模型的寿命[3]。

[动物实验]

大鼠[3]在300至350g大鼠（n = 5-10）中检查口服施用辅酶Q10对3-NP诱导的纹状体病变的影响。动物接受补充有200mg / kg辅酶Q10的大鼠食物或未补充的大鼠食物。 1周后，每天两次腹膜内注射3-NP，剂量为10 mgykg，直至对照组或治疗组动物出现后肢肌张力障碍症状，然后成对处死[3]。小鼠[3]为了确定辅酶Q10是否在人类神经退行性疾病的转基因小鼠模型中发挥神经保护作用，对过量表达人CuyZn超氧化物歧化酶（SOD1）突变的16只转基因小鼠口服给予辅酶Q10（200mg / kg），与13只接受未补充的大鼠食物的动物相比。使用的小鼠是G1系，其表达具有G93A突变的高水平的人SOD。出生后50天开始治疗。继续治疗直至小鼠达到终末期疾病[3]。

[参考文献]

[1]. Yang YK, et al. Coenzyme Q10 treatment of cardiovascular disorders of ageing including heart failure, hypertension and endothelial dysfunction. Clin Chim Acta. 2015 Oct 23;450:83-9.

[2]. Bhagavan HN, et al. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006 May;40(5):445-53.

[3]. Matthews RT, et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8892-7.

[相关活性小分子]

辅酶Q10物理化学性质

[ 密度 ]:
1.0±0.1 g/cm3

[ 沸点 ]:
869.0±65.0 °C at 760 mmHg

[ 熔点 ]:
49-51 °C

[ 分子式 ]:
C₅₉H₉₀O₄

[ 分子量 ]:
863.344

[ 闪点 ]:
324.6±34.3 °C

[ 精确质量 ]:
862.683899

[ PSA ]:
52.60000

[ LogP ]:
20.93

[ 外观性状 ]:
黄色-橙色结晶粉末

[ 蒸汽压 ]:
0.0±3.3 mmHg at 25°C

[ 折射率 ]:
1.526

[ 储存条件 ]:
−20°C

[ 稳定性 ]:
Stable, but may be light or heat sensitive. Store in the dark at -20 C. Incompatible with strong oxidizing agents.

[ 水溶解性 ]:
水溶性：不溶；可溶于：乙醚；极微溶：乙醇

辅酶Q10MSDS

详细MSDS(安全技术说明书)

辅酶Q10毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: DK3900000

CHEMICAL NAME :: p-Benzoquinone, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,1 8,22,26,30,34,38- tetracontadecaenyl)-5,6-dimethoxy-3-methyl-

CAS REGISTRY NUMBER :: 303-98-0

LAST UPDATED :: 199803

DATA ITEMS CITED :: 15

MOLECULAR FORMULA :: C59-H90-O4

MOLECULAR WEIGHT :: 863.49

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >4 gm/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,769,1972

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >500 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,769,1972

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >250 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,769,1972

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >500 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,769,1972

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >4 gm/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,769,1972

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >500 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,769,1972

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >500 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,769,1972

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >500 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,769,1972 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1400 mg/kg/5W-C

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - other changes Gastrointestinal - hypermotility, diarrhea Related to Chronic Data - death

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,769,1972 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 42 mg/kg

SEX/DURATION :: female 9-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - physical

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 3,306,1972

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 4200 mg/kg

SEX/DURATION :: female 9-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 3,306,1972

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 42 mg/kg

SEX/DURATION :: female 7-13 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - physical

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 3,306,1972

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 4200 mg/kg

SEX/DURATION :: female 7-13 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 3,306,1972

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 420 mg/kg

SEX/DURATION :: female 7-13 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 3,306,1972

点击显示

辅酶Q10安全信息

[ 个人防护装备 ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ 危害码 (欧洲) ]:
Xi: Irritant;

[ 风险声明 (欧洲) ]:
R36/37/38

[ 安全声明 (欧洲) ]:
22-24/25-26

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

[ RTECS号 ]:
DK3900000

[ 海关编码 ]:
2932999099

辅酶Q10合成路线

详细合成路线

辅酶Q10上下游产品

辅酶Q10上游产品

辅酶Q10下游产品

辅酶Q10制备

1.辅酶Q10可以由合成法和微生物发酵法生产。也可以从猪心肌中提取。

2.猪心肌渣皂化速冷皂化物萃取↓汽油

3.水洗减压浓缩过滤层析

4.减压浓缩结晶辅酶Q10结晶

5.提取细胞色素C后的心渣，以水漂洗去除（NH4）2SO4和脂肪，甩干，加入焦性没食子酸拌匀。另于回流罐中加入约2倍量乙醇，再加固体烧碱，搅拌溶解，配制成碱浓度约为10%（质量浓度）的醇碱溶液，然后投入拌有焦性没食子酸的心渣，迅速加热至沸，回流25～30min皂化。再迅速冷却至室温，在冷却的皂化物中，加入适量120号汽油，萃取三次，使萃取完全，合并萃取液，以水反复洗涤至近中性。将水洗后的萃取液减压浓缩至原体积的1/10左右，低温过滤除去析出的杂质（主要是胆固醇）。将澄清滤液加入硅胶层析柱。先用120号汽油洗涤去杂质，再用乙醚汽油混合液（1∶10，体积分数）洗脱，收集黄色带部分的洗脱液。在黄色油状洗脱液中，加入适量无水乙醇，温热使溶解完全。趁热过滤，滤液置冰箱中使结晶完全。滤得结晶，在无水乙醇中重结晶或经硅胶柱再层析，可得纯度更高的辅酶Q10。

6.除上述皂化法外，尚有溶剂直接提取法和溶剂提取皂化法。溶剂提取法的收率不如皂化法，但省除了应用焦没食子酸。较大量的焦没食子酸在皂化过程中可能产生乙氧基衍生物，皂化过程中也可充入氮气。正己烷、正庚烷、异辛烷、环己烷、乙醚以及乙醇和乙醚混合溶剂都可用来提取辅酶Q10。层析纯化的吸附剂可用硅胶和氧化铝等。

7. 烟草：FC，BU，1。

点击显示

辅酶Q10海关

[ 海关编码 ]: 2932999099

[ 中文概述 ]:
2932999099. 其他仅含氧杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途

[ Summary ]:
2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

辅酶Q10文献

Promotion of growth by Coenzyme Q10 is linked to gene expression in C. elegans

Biochem. Biophys. Res. Commun. 452(4) , 920-7, (2014)

• We systematically examined the relation between Coenzyme Q (CoQ) and growth in C. elegans. • Novel molecular targets differentially expressed by endogenous (clk-1 mutants) or exogenous CoQ are provi...

A nuclear role for the respiratory enzyme CLK-1 in regulating mitochondrial stress responses and longevity.

Nat. Cell Biol. 17 , 782-92, (2015)

The coordinated regulation of mitochondrial and nuclear activities is essential for cellular respiration and its disruption leads to mitochondrial dysfunction, a hallmark of ageing. Mitochondria commu...

Rapid high performance liquid chromatography-high resolution mass spectrometry methodology for multiple prenol lipids analysis in zebrafish embryos.

J. Chromatogr. A. 1412 , 59-66, (2015)

The analysis of lipid molecules in living organism is an important step in deciphering metabolic pathways. Recently, the zebrafish has been adopted as a valuable animal model system to perform in vivo...

更多文献

辅酶Q10相关知识

辅酶Q10的作用-副作用-辅酶Q10胶囊说明书

2019-01-12 19:34:40

导读：辅酶Q10，又名泛醌10，是一种脂溶性醌，其结构类似于维生素K，因其母核六位上的侧链——聚异戊烯基的聚合度为10而得名，是一种醌环类化合物。辅酶Q10在体内主要有两个作用，一是在营养物质在线粒体内转化为能量的过程中起重要的作用，二是有明显的抗脂质过氧化作用。【药品名称】通用名称：辅酶Q1...

抗衰老市场前景如何？抗衰老哪些生物活性成分效果最好？

2019-07-25 09:19:28

抗衰老是指预防，治疗和逆转与年龄有关的疾病，如年龄相关的斑点，疤痕和皱纹。根据之前的研究，2015年价值1403亿美元的抗衰老市场预计2016-2021年期间的复合年增长率（复合年增长率）为7.5％，最终触及约2165.2亿美元预测时间表。预计到2025年将达到2191亿美元，复合年增长率为8.0...

辅酶Q10

辅酶Q10用途

辅酶Q10作用

辅酶Q10名称

辅酶Q10生物活性

辅酶Q10物理化学性质

辅酶Q10MSDS

详细MSDS(安全技术说明书)

辅酶Q10毒性和生态

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

辅酶Q10安全信息

辅酶Q10合成路线

详细合成路线

辅酶Q10上下游产品

辅酶Q10上游产品

辅酶Q10下游产品

辅酶Q10制备

辅酶Q10海关

辅酶Q10文献

相关化工产品/化学物质：

相关药品：

推荐生产厂家/供应商：

辅酶Q10相关知识

相关化合物